Seeking Alpha
View as an RSS Feed

Micro Cap Sleuth  

View Micro Cap Sleuth's Comments BY TICKER:
Latest  |  Highest rated
  • Synthetic Biologics: A Speculative Small Cap Packed With Power [View article]
    Kirk would have to report selling via Form 4, though one might assume his holding company trades.
    Feb 10, 2015. 01:02 PM | 1 Like Like |Link to Comment
  • Synthetic Biologics: A Speculative Small Cap Packed With Power [View article]
    I concur Jared, having written an article here in December 2013 and since that time seeing Synthetic Biologics execution of one goal after the next. The company is managed smartly by Riley, and underwritten by the savviest of biotech investors.

    SYN resides in the stable with other successful RJ Kirk investments, XON and ZIOP, and could well prove to be one of the breakout biotechs of 2015-2020.
    Presently share price appreciation is muted due to a small shelf of warrants in the 1.70's, but I believe this affords a buying opportunity now.

    Cheers!
    Feb 10, 2015. 11:28 AM | 7 Likes Like |Link to Comment
  • Synthetic Biologics: Randal Kirk And A Robust Pipeline For 2014 [View article]
    CEO Riley, in his latest presentation at Roth, described 65% institutional ownership and a 35% float, as well as a new and unnamed "large" investor. Much more will be revealed in weeks and months to come.
    Mar 17, 2014. 05:58 AM | 1 Like Like |Link to Comment
  • Synthetic Biologics Under The Radar With Upcoming Multiple Sclerosis Data Catalyst [View article]
    If someone wants a Diet Coke, do they buy seltzer, aspartame, cola flavor, phenylanaline, and phosphorous and mix it all together, or do they buy a Diet Coke? My medium-sized city only has a few compounding pharmacies.
    There is depth to this pipeline far beyond Trimesta. SYN-004, the C-diff preventative, is in my opinion the key to the treasure here.
    Feb 19, 2014. 10:23 AM | 9 Likes Like |Link to Comment
  • Sequenom: Current Status [View article]
    "More covered lives and another national payer will put Sequenom over the top"

    News of Jan 9...http://yhoo.it/19VWGOS
    Jan 9, 2014. 06:06 PM | 3 Likes Like |Link to Comment
  • Synthetic Biologics: Randal Kirk And A Robust Pipeline For 2014 [View article]
    Below is the abstract of one study disavowing endometrial proliferation in relation to estriol, which has been in use and deemed safe for forty years. Also, Trimesta is a reformulation, so the jury is still out, so to speak. I have forwarded your question to SYN; whether or not they will respond to such an inquiry remains to be seen.

    Endometrial effect of oral estriol treatment in postmenopausal women.
    Englund DE, Johansson ED.
    Abstract

    Estriol is a weak estrogen with a claimed specific action on the epithelium in cervix uteri and vagina and with no or limited ability to induce endometrial proliferation. In a previous pharmacokinetic study we have shown elevated estriol levels for only 2-3 hours after oral administration of the drug. The present study was performed to test if estriol, when given orally in daily divided doses to postmenopausal women, has any effect on the endometrium. Twenty postmenopausal women who had no vaginal bleeding in response to lynestrenol (Orgametil 5 mgX2XV) were treated with 6 mg estriol a day (Ovesterin 2 mgX3), divided into three doses, for 2 up to 3.5 months. When lynestrenol (5 mgX2XV) was given following the estriol treatment periods, 12 women out of 20 experienced a vaginal bleeding and one reported spotting. Endometrial biopsies in ten of these women who had a bleeding were examined histologically. The endometrium was atrophic in four women, proliferative in two, slightly hyperplastic in one and showed signs of weak hormonal activity in one. Two women had secretory endometrium. It is concluded that estriol, administered in a way that gives prolonged elevation of the blood levels, is able to produce the same effect on the endometrium as other estrogens.
    Dec 29, 2013. 08:24 AM | Likes Like |Link to Comment
  • Synthetic Biologics: Randal Kirk And A Robust Pipeline For 2014 [View article]
    From my chart perspective, 1.42 then 1.36 need to hold. If SYN were to fail those levels, I would buy a dip to $1- 1.10 hand over fist.

    Like CYTR, which was subject to a classic shakeout prior to a mammoth run, SYN may well be run up and down around catalysts. Barring clinical failure, I'm a buyer on dips.

    Good luck!
    Dec 27, 2013. 12:21 PM | Likes Like |Link to Comment
  • Synthetic Biologics: Randal Kirk And A Robust Pipeline For 2014 [View article]
    Griffin calls for $4... traded SYN successfully a few times through this offering and subsequent volatility, but now plan only to accumulate on any retrace and let it ride....
    Dec 27, 2013. 12:14 PM | Likes Like |Link to Comment
  • Synthetic Biologics: Randal Kirk And A Robust Pipeline For 2014 [View article]
    Thanks for your comments...I would suggest stress and archaea as causative factors in IBS are by no means mutually exclusive. Every day we may be exposed to rhinovirus, but few have "cold" symptoms daily. Stress weakens our immune systems and renders us vulnerable to external pathogens. Hope your IBS never returns.
    Dec 27, 2013. 12:11 PM | 1 Like Like |Link to Comment
  • Cynapsus Therapeutics: A Significantly Undervalued Parkinson's Play [View article]
    Thanks Jason, looking forward to results of CTH-103.

    Cynapsus no-nonsense, methodical approach in developing their product and structuring and financing the company keeps me firm in my conviction this will play out well.
    Nov 26, 2013. 07:30 PM | 3 Likes Like |Link to Comment
  • Little-Known Cynapsus Underway To Solve Crucial Problem For Parkinson's Sufferers [View article]
    Some new analyst coverage. The other reports cited were highly bullish as well, and Noble reiterated their positive outlook the other day.

    http://bit.ly/1jG9U0D
    Nov 26, 2013. 11:30 AM | 1 Like Like |Link to Comment
  • Little-Known Cynapsus Underway To Solve Crucial Problem For Parkinson's Sufferers [View article]
    http://yhoo.it/18TYC3L

    Update: results to be published in Jan.
    Nov 21, 2013. 05:19 PM | 1 Like Like |Link to Comment
  • Little-Known Cynapsus Underway To Solve Crucial Problem For Parkinson's Sufferers [View article]
    No indication on when in Q4, but a solid answer that there are no delays. Before Christmas, one would expect.
    Nov 20, 2013. 10:15 AM | Likes Like |Link to Comment
  • Little-Known Cynapsus Underway To Solve Crucial Problem For Parkinson's Sufferers [View article]
    Can't really agree the stock got "crushed"...real problem here is liquidity. The stock has dropped from .38 to .34 on occasion on $340 trades, when someone sells a thousand shares. If there were dilutive selling or any real volume to the selling, I would be concerned.

    The sector has been under pressure, and CYNAF as a stock being as illiquid as it is has taken a larger-than-average dip, undeservedly in my opinion.
    Nov 20, 2013. 09:41 AM | Likes Like |Link to Comment
  • CytRx Awaiting Soft Tissue Sarcoma Data In December [View article]
    http://bit.ly/1dHswiI
    Adequate funding for trials and promise of "impressive" results
    Oct 29, 2013. 06:52 AM | 1 Like Like |Link to Comment
COMMENTS STATS
22 Comments
40 Likes